Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The firm's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Follow-Up Questions
¿Quién es el CEO de Haleon PLC?
Mr. Brian Mcnamara es el Chief Executive Officer de Haleon PLC, se unió a la empresa desde 2022.
¿Qué tal es el rendimiento del precio de la acción HLNCF?
El precio actual de HLNCF es de $4.71, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Haleon PLC?
Haleon PLC pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Haleon PLC?
La capitalización bursátil actual de Haleon PLC es $20.9B
¿Es Haleon PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 20 analistas han realizado calificaciones de análisis para Haleon PLC, incluyendo 8 fuerte compra, 9 compra, 8 mantener, 1 venta, y 8 fuerte venta
